Clinical trials: Pars Plana Vitrectomy
Cataract, Nuclear Progressive
The Post-Vitrectomy Lenstatin™ Study
To determine the efficacy of Lenstatin™, an over-the-counter nutritional supplement, in inhibiting the progression of nuclear cataract in eyes after pars plana vitrectomy.
- Trial name
- NCT02131194
- Testing
- Lenstatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Lenstatin LLC
Vitrectomy
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.
- Trial name
- NCT01319318
- Testing
- Pars Plana Vitrectomy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Pars Plana Vitrectomy
Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities
The primary objective of this study is to provide safety data for two different dosages of HydroLenz. Secondary objectives are to provide preliminary data to determine whether HydroLenz has the same effect in humans as it does in…
- Trial name
- NCT05592912
- Testing
- HydroLenz Injection, No HydroLenz Injection
- Sponsor
- PromiSight, LLC
Vitrectomy
Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to…
- Trial name
- NCT01229410
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 2 sites in United States, Czechia
- Volunteers
- 24 people
- Sponsor
- Allergan
Vitrectomy
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)
- Trial name
- MIVI-10 (NCT01159665)
- Testing
- ocriplasmin
- Where
- Belgium
- Volunteers
- 38 people
- Sponsor
- ThromboGenics